Overview Mechanism of action and resistance Pharmacokinetic and dosage Toxicity and side effects References
ChemicalBook > CAS DataBase List > Fluorocytosine

Fluorocytosine

Overview Mechanism of action and resistance Pharmacokinetic and dosage Toxicity and side effects References
Product Name
Fluorocytosine
CAS No.
2022-85-7
Chemical Name
Fluorocytosine
Synonyms
5-FLUOROCYTOSINE;FLUCYTOSINE;5-FC;ancobon;FLUCYTOSIN;5-FLUCYTOSINE;5-Flurocytosine;4-amino-5-fluoropyrimidin-2(1H)-one;Flurocytosine;5-fluorocytosin
CBNumber
CB6744939
Molecular Formula
C4H4FN3O
Formula Weight
129.09
MOL File
2022-85-7.mol
More
Less

Fluorocytosine Property

Melting point:
298-300 °C (dec.) (lit.)
Density 
1.3990 (estimate)
vapor pressure 
0Pa at 25℃
storage temp. 
2-8°C
solubility 
Sparingly soluble in water, slightly soluble in ethanol (96 per cent)
form 
Crystalline Powder
pka
3.26(at 25℃)
color 
White to almost white
Water Solubility 
1.5g/100mL (25 ºC)
Sensitive 
Light Sensitive
Merck 
14,4125
BRN 
127285
BCS Class
1
Stability:
Light Sensitive
InChIKey
XRECTZIEBJDKEO-UHFFFAOYSA-N
LogP
-1.36 at 22.1℃ and pH6.4-6.9
Dissociation constant
2.74-10.71 at 21.4℃
CAS DataBase Reference
2022-85-7(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xn,T,Xi
Risk Statements 
40-36/37/38-63
Safety Statements 
22-24/25-45-36/37-36/37/39-27-26
WGK Germany 
2
RTECS 
HA6040000
F 
10-23
Hazard Note 
Toxic/Light Sensitive
HazardClass 
IRRITANT, LIGHT SENSITIVE
HS Code 
29335990
Hazardous Substances Data
2022-85-7(Hazardous Substances Data)
Toxicity
LD50 in mice (mg/kg): >2000 orally and s.c.; 1190 i.p.; 500 i.v. (Grunberg, 1963)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H361Suspected of damaging fertility or the unborn child

Precautionary statements

P280Wear protective gloves/protective clothing/eye protection/face protection.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
F7129
Product name
5-Fluorocytosine
Purity
nucleoside analog
Packaging
1g
Price
$260
Updated
2024/03/01
Sigma-Aldrich
Product number
1272000
Product name
Flucytosine
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$436
Updated
2024/03/01
TCI Chemical
Product number
F0321
Product name
5-Fluorocytosine
Purity
>98.0%(HPLC)(T)
Packaging
1g
Price
$38
Updated
2024/03/01
TCI Chemical
Product number
F0321
Product name
5-Fluorocytosine
Purity
>98.0%(HPLC)(T)
Packaging
5g
Price
$110
Updated
2024/03/01
Alfa Aesar
Product number
L16496
Product name
5-Fluorocytosine, 98+%
Packaging
250mg
Price
$35.65
Updated
2024/03/01
More
Less

Fluorocytosine Chemical Properties,Usage,Production

Overview

A fluorinated pyrimidine, 5-flucytosine (fluorocytosine; 5-FC, Fig. 1), was initially developed as a potential anti-cancer agent but it was not sufficiently effective in the field of cancer chemotherapy[1]. Later, 5-FC proved to be active in experimental candidiasis and cryptococcosis in mice[2] and was used to treat human infections[3]. In addition to its activity against Candida and Cryptococcus, 5-FC also has an inhibitory activity against fungi causing chromoblastomycosis[4]; however, it is ineffective against infections caused by filamentous fungi. 5-FC has a high prevalence of primary resistance in many fungal species. Due to this primary resistance, 5-FC is used mainly in combination with other antifungals (primarily amphotericin B, AmB) and more recently it has been investigated in combination with other agents including fluconazole (FLU), ketoconazole (KTZ), itraconazole (ITRA), voriconazole (VORI) and echinocandins (e.g., micafungin, MICA and caspofungin, CAS). It is used only rarely as a single agent.
Flucytosine (5-FC) is a synthetic antimycotic compound, first synthesized in 1957. It has no intrinsic antifungal capacity, but after it has been taken up by susceptible fungal cells, it is converted into 5-fluorouracil (5-FU), which is further converted to metabolites that inhibit fungal RNA and DNA synthesis. Monotherapy with 5-FC is limited because of the frequent development of resistance. In combination with amphotericin B, 5-FC can be used to treat severe systemic mycoses, such as cryptococcosis, candidosis, chromoblastomycosis and aspergillosis.

Figure 1 the chemical structure of Fluorocytosine

Mechanism of action and resistance

5-FC is most active against yeasts, including Candida, Torulopsis and Cryptococcus spp., and against the dematiaceous fungi causing chromomycosis (Phialophora and Cladosporium spp.) and Aspergillus spp.[5] The MICs of 5-FC vary from 0.1 to 0.25 mg/L for these fungal species.
In Emmonsia crescens, Emmonsia parva, Madurella mycetomatis, Madurella grisea, Pyrenochaeta romeroi, Cephalosporium spp., Sporothrix schenckii and Blastomyces dermatitidis, MICs vary from 100 to 1000 mg/L.14 5-FC is also active against some protozoa, including Acanthamoeba culbertsoni both in vitro and in vivo and Leishmania spp. in patients.[5]
Antimycotic activity of 5-FC results from its rapid conversion into 5-fluorouracil (5-FU) by the enzyme cytosine deaminase, within susceptible fungal cells. There are two mechanisms involved by which 5-fluorouracil exerts its antifungal activity. The first mechanism includes the conversion of 5-fluorouracil through 5-fluorouridine monophosphate (FUMP) and 5-fluorouridine diphosphate (FUDP) into 5-fluorouridine triphosphate (FUTP)[6]. FUTP is further incorporated into fungal RNA in place of uridylic acid; this alters the aminoacylation of tRNA, disturbs the amino acid pool and inhibits protein synthesis[6]. The second mechanism is the metabolism of 5-FU into 5-fluorodeoxyuridine monophosphate (FdUMP) by uridine monophosphate pyrophosphorylase[6]. FdUMP is a potent inhibitor of thymidylate synthase, which is a key enzyme involved in DNA synthesis and nuclear division[7]. Thus, 5-FC acts by interfering with pyrimidine metabolism and protein synthesis in the fungal cell. These activity results in cell lysis and death.
The occurrence of resistance with the use of 5-FC has been widely described and precludes use of 5-FC as a single agent[8, 10] Two basic mechanisms of resistance can be distinguished: (i) certain mutations can result in a deficiency in the enzymes necessary for cellular transport and uptake of 5-FC or for its metabolism (i.e. cytosine permease, uridine monophosphate pyrophosphorylase or cytosine deaminase);[9,11] (ii) resistance may result from increased synthesis of pyrimidines, which compete with the fluorinated antimetabolites of 5-FC and thus diminish its antimycotic activity.[9] It has been shown that defective uridine monophosphate pyrophosphorylase is the most frequently occurring type of acquired 5-FC resistance in fungal cells.[12] Normark & Schönebeck have reported that two different phenotypes of 5-FC-resistant strains can be recognized:[10] strains of resistance phenotype class 1 are not affected by 5-FC at high concentrations (these are the totally (intrinsically) resistant strains), while those of class 2 are susceptible to 5-FC at low concentrations but, after long exposure to 5-FC (even at high concentrations) resistance develops (these are said to be partially resistant or to have acquired resistance). Development of resistance in the latter strains probably results from selection of non-susceptible mutants, leading to a secondary resistant population.[9]
The incidence of resistance to 5-FC varies between species.20 Up to 7–8% of intrinsically resistant strains are found among pretreatment isolates of C. albicans, unspeciated candida and Torulopsis glabrata. In C. neoformans the incidence of resistance is lower (1–2%), but in Candida spp. other than C. albicans it is 22%, because of the prevalence of generally less sensitive species such as Candida tropicalis and Candida krusei[13]. The exact incidence of primary 5-FC resistance is not clear. Different investigators report rates ranging between 8% and 44% for Candida spp[14]. Possible factors contributing to this wide range include the susceptibility methods used, local factors involving use of antifungal agents and differences in the prevalence of various Candida spp[14].

Pharmacokinetic and dosage

5-FC is absorbed very rapidly and almost completely: 76–89% is bioavailable after oral administration.[16] In patients with normal renal function, peak concentrations are attained in serum and other body fluids within 1–2 h.[15, 16]. 5-FC penetrates well into most body sites, including cerebrospinal, vitreous and peritoneal fluids, and into inflamed joints, because it is small and highly water-soluble and is not bound by serum proteins to a great extent[15-17]. 5-FC is principally eliminated by the kidneys and the plasma clearance of the drug is closely related to creatinine clearance[15, 17]. 5-FC is only minimally metabolized in the liver. Renal elimination is via glomerular filtration; no tubular resorption or secretion takes place. The half-life of 5-FC is c.3–4 h in patients with normal renal function, but can be extended up to 85 h in patients with severe renal insufficiency.[12, 16, 18] Renal insufficiency alters 5-FC pharmacokinetics since it slows absorption, prolongs serum half-life and decreases clearance[15]. The apparent volume of distribution of 5-FC approaches that of total body water and is not altered by renal failure.
Dosage must be adjusted in patients with renal impairment. Various recommendations have been made[15-18]. Daneshmend & Warnock have suggested the following guidelines for the administration of 5-FC to patients with renal insufficiency.[15]. In patients with a creatinine clearance of >40 mL/min, a standard dose of 37.5 mg/kg every 6 h should be used. If the creatinine clearance is between 20 and 40 mL/min, the recommended dose is 37.5 mg/kg every 12 h. In patients with a creatinine clearance of <20 mL/ minute, the dose of 5-FC should be 37.5 mg/kg once daily. Finally, if the creatinine clearance is <10 mL/min, frequent determinations of 5-FC concentration should be used as guidance for the frequency of dosing.

Toxicity and side effects

5-FC is known to have some relatively minor side effects, such as nausea, vomiting and diarrhoea, it also has more severe side effects, including hepatotoxicity and bonemarrow depression. Gastrointestinal side effects, the most common and least harmful side effects associated with 5-FC treatment, include nausea, diarrhoea and, occasionally, vomiting and diffuse abdominal pain. They occur in approximately 6% of patients treated with 5-FC[18]. Although these side effects are usually not severe; two cases of ulcerative colitis and bowel perforation have been reported[19]. Hepatotoxicity can occur during 5-FC treatment. In most cases it involves increases in serum concentrations of transaminases and alkaline phosphatase[20]. The incidence of hepatotoxicity is between 0 and 25%[20]. The most severe toxicity associated with 5-FC treatment are bone-marrow depression. There have been several reports of serious or life-threatening leucocytopenia, thrombocytopenia and/or pancytopenia[21-23]. The mechanism of toxicity of 5-FC is still not fully understood. It is likely that some of the side effects caused by 5-FC, for example hepatotoxicity and bone-marrow depression, are dose-dependent, although not all reports support this theory. Furthermore, it has been postulated that conversion of 5-FC to certain metabolites, especially 5-FU, could be one of the mechanisms of development of 5-FC-associated toxicity.

References

  1. Heidelberg C, Chaudhuri NK, Danneberg P et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179(4561): 663–666
  2. Grunberg E, Titsworth E, Bennett M. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother 1963; 161:566–568
  3. Tassel D, Madoff MA. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA 1968; 206(4): 830–832
  4. Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm 1988; 7(6): 424–438
  5. Scholer, H. J. (1980). Flucytosine. In Antifungal Chemotherapy, (Speller, D. C. E., Ed.), pp. 35–106. Wiley, Chichester.
  6. Waldorf AR, Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother 1983; 23(1):79–85
  7. Diasio RB, Bennett JE, Myers CE. Mode of action of 5-fluorocytosine. Biochem Pharmacol 1978; 27(5):703–707
  8. Polak, A. & Scholer, H. J. (1975). Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 21, 113–30.
  9. Polak, A. (1977). 5-Fluorocytosine—current status with special references to mode of action and drug resistance. Contributions to Microbiology and Immunology 4, 158–67.
  10. Normark, S. & Schönebeck, J. (1973). In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrobial Agents and Chemotherapy 2, 114–21.
  11. Fasoli, M. & Kerridge, D. (1988). Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species. Annals of the New York Academy of Sciences 544, 260–3.
  12. Francis, P. & Walsh, T. J. (1992). Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clinical Infectious Diseases 15, 1003–18.
  13. Medoff, G. & Kobayashi, G. S. (1980). Strategies in the treatment of systemic fungal infections. New England Journal of Medicine 302, 145–55.
  14. Armstrong, D. & Schmitt, H. J. (1990). Older drugs. In Chemotherapy for Fungal Diseases, (Ryley, J. F., Ed.), pp. 439–54. Springer-Verlag, Berlin.
  15. Daneshmend, T. K. & Warnock, D. W. (1983). Clinical pharmacokinetics of systemic antifungal drugs. Clinical Pharmacokinetics 8, 17–42.
  16. Cutler, R. E., Blair, A. D. & Kelly, M. R. (1978). Flucytosine kinetics in subjects with normal and impaired renal function. Clinical Pharmacology and Therapeutics 24, 333–42.
  17. Block, E. R., Bennett, J. E., Livoti, L. G., Klein, W. J., MacGregor, R. R. & Henderson, L. (1974). Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Annals of Internal Medicine 80, 613–7.
  18. Schönebeck, J., Polak, A., Fernex, M. & Scholer, H. J. (1973). Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 18, 321–36.
  19. Benson, J. M. & Nahata, M. C. (1988). Clinical use of systemic antifungal agents. Clinical Pharmacy 7, 424–38.
  20. Bennet, J. E. (1977). Flucytosine. Annals of Internal Medicine 86, 319–21.
  21. Kauffman, C. A. & Frame, P. T. (1977). Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrobial Agents and Chemotherapy 11, 244–7.
  22. Schlegel, R. J., Bernier, G. M., Bellanti, J. A., Maybee, D. A., Osborne, G. B., Stewart, J. L. et al. (1970). Severe candidiasis associated with thymic dysplasia, IgA deficiency, and plasma antilymphocyte effects. Pediatrics 45, 926–36.
  23. Meyer, R. & Axelrod, J. L. (1974). Fatal aplastic anemia resulting from flucytosine. Journal of the American Medical Association 228, 1573.

Description

5-Fluorocytosine (5-FC), a fluorinated pyrimidine analog, is a synthetic antimycotic prodrug that is converted by cytosine deaminase to 5-fluorouracil. 5-Fluorouracil, a widely used cytotoxic drug, is further metabolized to fluorinated ribo- and deoxyribonucleotides, resulting in the inhibition of DNA and protein synthesis, which has multiple effects including inhibition of Candida species and C. neoformans infections and cytotoxicity towards cancer cells. In combination with a retroviral replicating vector carrying a cytosine deaminase prodrug-activating gene, 5-FC has been shown to selectively eliminate CT26 and Tu-2449 tumor cells in vitro (IC50s = 4.2 and 1.5 μM, respectively) and to significantly improve survival and reduce tumor size (at a dose of 500 mg/kg) in two different syngeneic mouse glioma models.

Chemical Properties

White Crystalline Solid

Originator

Ancobon,Roche,US,1972

Uses

5-Fluorocytosine acts as an antidiabetic, antifungal and antimicrobial agent. It is useful for the treatment of serious infections arises due to susceptible strains of Candida or Cryptococcus neoformans and chromomycosis. Further, it is employed in studies on TMP biosynthesis.

Uses

5-FC is a toxic antifungal/antimicrobial agent

Indications

Flucytosine (Ancobon) is a synthetic, fluorinated pyrimidine that is structurally related to fluorouracil (FU) and floxuridine. It can be fungistatic and fungicidal. Although it is used more frequently in the treatment of systemic infections caused by Candida and Cryptococcus, dermatologic indications may include infections due to chromomycosis, sporotrichosis, Cladosporium, and Sporothrix species. It is generally ineffective against Aspergillus species.

Definition

ChEBI: Flucytosine is an organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections. It has a role as a prodrug. It is an organofluorine compound, a pyrimidone, an aminopyrimidine, a nucleoside analogue and a pyrimidine antifungal drug. It is functionally related to a cytosine.

Manufacturing Process

The preparation of 5-fluorouracil is given under "Fluorouracil." As described in US Patent 3,040,026, 5-fluorouracil is then subjected to the following steps to give flucytosine.
Step 1: 2,4-Dichloro-5-Fluoropyrimidine - A mixture of 104 grams (0.8 mol) of 5-fluorouracil, 1,472 grams (9.6 mols) of phosphorus oxychloride and 166 grams (1.37 mols) of dimethylaniline was stirred under reflux for 2 hours. After cooling to room temperature, phosphorus oxychloride was removed by distillation at 18 to 22 mm and 22° to 37°C. The residue was then poured into a vigorously stirred mixture of 500 ml of ether and 500 gram of ice. After separating the ether layer, the aqueous layer was extracted with 500 ml, then 200 ml of ether. The combined ether fractions were dried over sodium sulfate, filtered, and the ether removed by vacuum distillation at 10° to 22°C. The residue, a yellow solid melting at 37° to 38°C, weighed 120 grams corresponding to a 90% yield. Vacuum distillation of 115 grams of this material at 74° to 80°C (16 mm) gave 108 grams of white solid melting at 38° to 39°C corresponding to an 84.5% yield.
Step 2: 2-Chloro-4-Amino-5-Fluoropyrimidine - To a solution of 10.0 grams (0.06 mol) of 2,4-dichloro-5-fluoropyrimidine in 100 ml of ethanol, 25 ml of concentrated aqueous ammonia were slowly added. A slightly opalescent solution resulted. The temperature gradually rose to 35°C. The solution was then cooled in ice to 18°C and thereafter remained below 30°C. After three hours, a Volhard titration showed that 0.0545 mol of chlorine was present in ionic form. Storage in a refrigerator overnight resulted in some crystallization of ammonium chloride. A white sludge, resulting from the evaporation of the reaction mixture at 40°C, was slurried with 75 ml of water, filtered and washed free of chloride. After drying in vacuo, the product melted at 196.5° to 197.5°C, yield 6.44 grams. Evaporation of the mother liquors yielded a second crop of 0.38 gram, raising the total yield to 6.82 grams (79.3%).
Step 3: 5-Fluorocytosine - A slurry of 34.0 grams (0.231 mol) of 2-chloro-4- amino-5-fluoropyrimidine in 231 ml of concentrated hydrochloric acid was heated in a water bath at 93° to 95°C for 125 minutes. The reaction was followed by means of ultraviolet spectrophotometry using the absorption at 245, 285, and 300 mμ as a guide. The absorption at 300 mμ rose to a maximum after 120 minutes and then dropped slightly. The clear solution was cooled to 25°C in an ice bath, then evaporated to dryness under vacuum at 40°C. After slurrying with water three times and reevaporating, the residue was dissolved in 100 milliliters of water. To this solution, cooled in ice, 29 ml of concentrated ammonia were added dropwise. The resulting precipitate was filtered, washed free of chloride with water, then with alcohol and ether. After drying in vacuo at 65°C, the product weighed 22.3 grams. An additional 6.35 grams was obtained by evaporation of the mother liquor, thus yielding a total of 28.65 grams (96.0%).

brand name

Ancobon (Valeant).

Therapeutic Function

Antifungal

Antimicrobial activity

The spectrum of activity is restricted to Candida spp., Cryptococcus spp. and some fungi causing chromoblastomycosis.

Acquired resistance

About 2–3 of Candida spp. isolates (more in some centers) are resistant before treatment starts, and resistance may develop during treatment. The most common cause of resistance appears to be loss of the enzyme uridine monophosphate pyrophosphorylase.

Pharmaceutical Applications

A synthetic fluorinated pyrimidine available for intravenous infusion or oral administration.

Biochem/physiol Actions

Nucleoside analog that has antifungal activities. 5-FC is deaminated by cytosine deaminase to product 5-fluorouracil, resulting in RNA miscoding. 5-Fluorocytosine inhibits DNA and RNA synthesis and interferes with ribosomal protein synthesis.

Mechanism of action

Flucytosine (5-flucytosine, 5-FC; Ancoban) is a fluorinated pyrimidine analogue of cytosine that was originally synthesized for possible use as an antineoplastic agent. It is indicated only for the treatment of serious systemic infections caused by susceptible strains of Candida and Cryptococcus spp.The mechanism of action of 5-fluorocytosine (5-FC)has been studied in detail.The drug enters the fungal cell by active transport onATPases that normally transport pyrimidines. Once insidethe cell, 5-fluorocytosine is deaminated in a reaction catalyzedby cytosine deaminase to yield 5-fluorouracil(5-FU). 5-Fluorouracil is the active metabolite of the drug.5-Fluorouracil enters into pathways of both ribonucleotideand deoxyribonucleotide synthesis. The fluororibonucleotidetriphosphates are incorporated into RNA, causingfaulty RNA synthesis. This pathway causes cell death. Inthe deoxyribonucleotide series, 5-fluorodeoxyuridinemonophosphate (F-dUMP) binds to 5,10-methylenetetrahydrofolicacid, interrupting the one-carbon pool substratethat feeds thymidylate synthesis. Hence, DNA synthesisis blocked.

Pharmacology

5-FC is well absorbed orally, with greater than 90% bioavailability. The serum half-life is 3 to 5 hours, with serum levels peaking 4 to 6 hours after a single dose.The drug is widely distributed in body fluids, with cerebrospinal fluid levels 60 to 80% of serum levels.The drug also penetrates well into urine, aqueous humor, and bronchial secretions.Minimal serum protein binding allows more than 90% of each dose to be excreted in the urine; significant dosage reductions are required in the presence of renal impairment. 5-FC can be removed by both hemodialysis and peritoneal dialysis. 5-FC conversion to toxic metabolites may occur in mammalian cells to a limited extent, which accounts for 5-FC toxicity.

Pharmacokinetics

Oral absorption: Complete
Cmax 25 mg/kg 6-hourly oral: 70–80 mg/L after 1–2 h
Plasma half-life: 3–6 h
Volume of distribution: 0.7–1 L/kg
Plasma protein binding c. 12%
Absorption is slower in persons with impaired renal function, but peak concentrations are higher. Levels in the CSF are around 75% of the simultaneous serum concentration. More than 90% of a dose of flucytosine is excreted in the urine in unchanged form. The serum half-life is much longer in renal failure, necessitating modification of the dosage regimen: for patients with a creatinine clearance below 40 mL/ min the dosage interval should be doubled to 12 h; in severe renal failure the dosage interval should be further increased to once daily or less, based on frequent serum drug concentration measurements.

Clinical Use

Flucytosine has significant antifungal activity against C. albicans, other Candida spp., C. neoformans, and the fungal organisms responsible for chromomycosis. Not considered the drug of choice for these fungal infections, 5-FC does remain useful as part of combination therapy for systemic candidiasis and cryptococcal meningitis and as an alternative drug for chromomycosis. When it is used as monotherapy, resistance and clinical failure are common. Potential mechanisms for drug resistance include decreased fungal cell membrane permeability and reduced levels of fungal cytosine deaminase. Combination therapy with amphotericin B and flucytosine in the treatment of cryptococcal meningitis and deep-seated Candida infections, such as septic arthritis and meningitis, permits reduced dosing of amphotericin B and prevents the emergence of 5-FC resistance. When higher doses of amphotericin B are used, combination therapy with 5-FC confers no additional clinical benefit except in the treatment of Candida endophthalmitis, where tissue penetration remains problematic.

Clinical Use

Candidosis (in combination with amphotericin B or fluconazole)
Cryptococcosis (in combination with amphotericin B or fluconazole)
Monitoring of flucytosine concentrations is desirable in all patients, and mandatory in those with renal impairment.

Side effects

Nausea, vomiting, abdominal pain and diarrhea are common. Serious side effects include myelosuppression and hepatic toxicity; they occur more frequently when serum concentrations exceed 100 mg/L.
The nephrotoxic effects of amphotericin B can result in elevated blood concentrations of flucytosine, and levels of the latter drug should be monitored when these compounds are administered together. When 5-FC is prescribed alone to patients with normal renal function, skin rash, epigastric distress, diarrhea, and liver enzyme elevations can occur.

Synthesis

Flucytosine, 5-fluorocytosine (35.4.4), is synthesized from fluorouracil (30.1.3.3). Fluorouracil is reacted with phosphorous oxychloride in dimethylaniline to make 2,4-dichloro-5-fluoropyrimidine (35.4.2), which is reacted with ammonia to make a product substituted with chlorine at the fourth position of the pyrimidine ring&mdash;4-amino- 2-chloro-5-fluoropyrimidine (35.4.3). Hydrolysis of the chlorovinyl fragment of this compound in a solution of hydrochloric acid gives the desired flucytosine.

An alternative way of synthesis consists of making flucytosine from a precursor of fluorouracil&mdash;5-fluoro-2-methylthiouracil (30.1.3.2) using a somewhat analogous scheme. Treating 5-fluoro-2-methylthiouracil (30.1.3.2) with phosphorous pentachloride gives 4-chloro-5-fluoro-2-methylthiopyrimidine (35.4.5), which upon being reacted with ammonium is transformed into 4-amino-5-fluoro-2-methylthiopyrimidine (35.4.6). Hydrolysis of the methylthiovinyl fragment using concentrated hydrobromic acid gives the desired flucytosine.

Drug interactions

Potentially hazardous interactions with other drugs
Cytarabine: concentration of flucytosine possibly reduced.

Metabolism

Flucytosine itself is not cytotoxic but, rather, is a pro-drug that is taken up by fungi and metabolized to 5-fluorouracil (5-FU) by fungal cytidine deaminase. Then, 5-FU is converted to 5-fluorodeoxyuridine, which as a thymidylate synthase inhibitor interferes with both protein and RNA biosynthesis. 5-Fluorouracil is cytotoxic and is employed in cancer chemotherapy. Human cells do not contain cytosine deaminase and, therefore, do not convert flucytosine to 5-FU. Some intestinal flora, however, do convert the drug to 5-FU, so human toxicity does result from this metabolism.

Fluorocytosine Preparation Products And Raw materials

Raw materials

N-Methylaniline 2,4-Dichloro-5-fluoropyrimidine 5-FLUORO-4-HYDROXY-2-METHOXYPYRIMIDINE Phosphorus oxychloride 4-Amino-2-chloro-5-fluoropyrimidine 5-Fluorouracil

Preparation Products

More
Less

Fluorocytosine Suppliers

Americas 1 Belgium 1 Canada 5 China 649 Egypt 1 Europe 6 France 3 Germany 9 Hungary 1 India 58 Japan 5 Poland 1 Russia 2 Slovakia 1 South Korea 1 Switzerland 6 The Netherlands 1 United Kingdom 24 United States 68 Global 843
Wuhan woxuan Technology Co., Ltd
Tel
13322067656
Email
3199863540@qq.com
Country
China
ProdList
5139
Advantage
58
China Synchem Technology Co.,Ltd.
Tel
+86-0552-4929304 +86-18055277008
Fax
+86-552-4928800
Email
sales@cnsynchem.com
Country
China
ProdList
55
Advantage
65
Shanghai Zhuorui Chemical Co.,Ltd.
Tel
021-69180038
Fax
0086-21-39177059
Email
zhuoruichem@163.com
Country
China
ProdList
105
Advantage
58
Shangfluoro
Tel
021-021-65170832 13331983812
Email
qinba_2@163.com
Country
China
ProdList
301
Advantage
58
Zhejiang Chenxi Technology Co., LTD
Tel
13552015630
Email
3558143071@qq.com
Country
China
ProdList
503
Advantage
58
Jiangsu Zhongyuan Chemicals Co.,Ltd.
Tel
0513-84539538 13817775327
Email
jinjing860329@163.com
Country
China
ProdList
19
Advantage
58
Jinan Sanyuan Chemical Co. LTD
Tel
0531-58582194 13335164090
Fax
0531-58585914
Email
1660423085@qq.com
Country
China
ProdList
400
Advantage
58
Xinxiang Yicheng Biotechnology Co.,LTD
Tel
0373-6014999 18937330588
Email
xxycswsale@163.com
Country
China
ProdList
55
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Changzhou Sunchem Pharmaceutical Chemical Material Co.,Ltd.
Tel
0519-85195575 15861192208
Fax
85195585
Email
850305@sunkechem.com
Country
China
ProdList
77
Advantage
69
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
4006608290; 18621169109
Fax
86-21-61259102
Email
market03@meryer.com
Country
China
ProdList
40241
Advantage
62
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Fax
86-21-50328109
Email
3bsc@sina.com
Country
China
ProdList
15848
Advantage
69
future industrial shanghai co., ltd
Tel
400-0066400 13621662912
Fax
021-55660885
Email
sales@jonln.com
Country
China
ProdList
1998
Advantage
65
Alfa Aesar
Tel
400-6106006
Fax
021-67582001/03/05
Email
saleschina@alfa-asia.com
Country
China
ProdList
30132
Advantage
84
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Fax
021-67121385
Email
Sales-CN@TCIchemicals.com
Country
China
ProdList
24539
Advantage
81
BeiJing Hwrk Chemicals Limted
Tel
0757-86329057 18501085097
Fax
010-89508210
Email
sales3.gd@hwrkchemical.com
Country
China
ProdList
7583
Advantage
55
Energy Chemical
Tel
021-021-58432009 400-005-6266
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
44751
Advantage
61
Wuhan Chemwish Technology Co., Ltd
Tel
86-027-67849912
Fax
86-027-87531808
Email
sales@chemwish.com
Country
China
ProdList
35906
Advantage
56
Shanghai Sinch Parmaceuticals Tech. Co. Ltd.
Tel
+86-21-54098501
Fax
+86-21-54096319
Email
sales@sinch.com.cn
Country
China
ProdList
11605
Advantage
64
Jia Xing Isenchem Co.,Ltd
Tel
0573-85285100 18627885956
Fax
0573-85285100
Email
isenchem@163.com
Country
China
ProdList
9551
Advantage
66
Wuhu Huaren Science and Technology Co., Ltd.
Tel
0553-0553-5842013-801 18155347026
Fax
086-553-5843138
Email
sale@huarensh.com
Country
China
ProdList
296
Advantage
64
Accela ChemBio Co.,Ltd.
Tel
021-50795510 4000665055
Fax
021-50795055
Email
sales@accelachem.com
Country
China
ProdList
11660
Advantage
64
Shanghai Longsheng chemical Co.,Ltd.
Tel
021-58099652-8005 13585536065
Fax
021-58099609
Email
bin.wu@shlschem.com
Country
China
ProdList
9816
Advantage
59
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696;
Email
info@hanhongsci.com
Country
China
ProdList
42982
Advantage
64
Chemsky（shanghai）International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32344
Advantage
50
XiaoGan ShenYuan ChemPharm co,ltd
Tel
15527768850
Email
1791901229@qq.com
Country
China
ProdList
8849
Advantage
52
Beijing Isomersyn Technology CO;LTD
Tel
010-82954736 13391601435
Email
sales@isomersyn.com
Country
China
ProdList
3296
Advantage
57
Chemipanda Bio-Tech Co., Ltd.
Tel
+86-571-85224801; 13588483690
Fax
0571-85241599
Email
chemipanda2010@163.com
Country
China
ProdList
107
Advantage
62
Shandong Xiya Chemical Co., Ltd
Tel
13355009207 13355009207
Fax
0539-6365991
Email
3007715519@qq.com
Country
China
ProdList
18739
Advantage
57
Syntechem Co.,Ltd
Tel
Fax
E-Mail Inquiry
Email
info@syntechem.com
Country
China
ProdList
12990
Advantage
57
BEST-REAGENT
Tel
400-1166-196 18981987031
Fax
028-84555506 800101999
Email
cdhxsj@163.com
Country
China
ProdList
11726
Advantage
57
China Langchem Inc.
Tel
0086-21-58956006
Fax
0086-21-58956100
Country
China
ProdList
7815
Advantage
57
Tianjin heowns Biochemical Technology Co., Ltd.
Tel
400 638 7771
Email
sales@heowns.com
Country
China
ProdList
14443
Advantage
57
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Fax
86-21-63290778 86-21-63218885
Email
sj_scrc@sinopharm.com
Country
China
ProdList
9823
Advantage
79
Nanjing Vital Chemical Co., Ltd.
Tel
Please Send Email 18652950785
Fax
025-87193546
Email
chemweiao@163.com
Country
China
ProdList
4388
Advantage
65
Maya High Purity Chemicals
Tel
+86 (573) 82222445 (0)18006601000 452520369
Fax
+86 (573) 82222643
Email
sales@maya-r.com
Country
China
ProdList
11714
Advantage
57
ZhengZhou HuaWen Chemical Co.Ltd
Tel
0370-2785118 15343847665
Fax
QQ：3470079902
Email
huawenchem@163.com
Country
China
ProdList
3206
Advantage
55
Shanghai Sphchem Co., Ltd.
Tel
21-21-56491756 13512199871
Fax
021-5649-1756
Email
sales@panhongchem.com
Country
China
ProdList
4001
Advantage
55
Spectrum Chemical Manufacturing Corp.
Tel
021-021-021-67601398-809-809-809 15221380277
Fax
021-57711696
Email
marketing_china@spectrumchemical.com
Country
China
ProdList
9664
Advantage
60
TaiZhou ZhiCheng Chemicals & Technology Co., LTD.
Tel
0523-82837785 13365232216
Fax
0523-87913272
Email
info@jszchg.com
Country
China
ProdList
245
Advantage
60
Wuhan Fortuna Chemical Co., Ltd
Tel
027-027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2893
Advantage
58
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4647
Advantage
58
Wuhan Haizheng Industry & Trade Development Co. Ltd
Tel
027-8866 0053/88660577/88660578
Fax
027-8899 1911
Country
China
ProdList
1076
Advantage
55
BioBioPha Co., Ltd.
Tel
0871-65217109 13211707573;
Fax
0871-65215563
Email
y.liu@mail.biobiopha.com
Country
China
ProdList
5654
Advantage
65
Changzhou Joyous Chemical Co., Ltd.
Tel
0519-85607258
Fax
0519-85607278
Email
sales@joyouschem.com
Country
China
ProdList
296
Advantage
60
ShangHai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847 13636370518
Fax
021-55068248
Email
shyysw007@163.com
Country
China
ProdList
4941
Advantage
60
Chengdu Ai Keda Chemical Technology Co., Ltd.
Tel
4008-755-333 18080918076
Fax
028-86757656
Email
800078821@qq.com
Country
China
ProdList
9725
Advantage
55
T&W GROUP
Tel
021-61551611 13296011611
Fax
＋86 21-50676805
Email
contact@trustwe.com
Country
China
ProdList
9900
Advantage
58
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660
Fax
86-21-34053661
Email
sale@labgogo.com
Country
China
ProdList
9872
Advantage
52
Suzhou Sibian Chemical Technology Co.,Ltd.
Tel
0512-65617459 18915409046
Fax
0512-65617459
Email
sales@sibian-chem.com
Country
China
ProdList
1927
Advantage
55
More
Less

View Lastest Price from Fluorocytosine manufacturers

hebei hongtan Biotechnology Co., Ltd
Product
Fluorocytosine 2022-85-7
Price
US $30.00/kg
Min. Order
1kg
Purity
98%
Supply Ability
2000kg
Release date
2024-03-22
Shaanxi Haibo Biotechnology Co., Ltd
Product
5-Flucytosine 2022-85-7
Price
US $0.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
2000ton
Release date
2023-09-04
Guangzhou Tosun Pharmaceutical Limited
Product
Capecitabine Intermediate 1 2022-85-7
Price
US $0.00/mg
Min. Order
10mg
Purity
99%
Supply Ability
1kg/month
Release date
2023-05-10

2022-85-7, FluorocytosineRelated Search:

Cytosine Tris(hydroxymethyl)aminomethane 2-Chloro-5-fluoropyrimidine ALTRENOGEST 5-Fluorouracil 3-Aminophenol 4-Aminopyrimidine 6-Aminocaproic acid 5-Fluoropyrimidine CHLOROPHOSPHONAZO III Glycine 5-Fluorocytidine Fluorine pyrimidone Emtricitabine Capecitabine Galocitabine 5'-Deoxy-5-fluorocytidine

  • 4-amino-5-fluoro-2(1h)-pyrimidinon
  • 4-Amino-5-fluoro-2(1H)-pyrmidinone
  • 5-fluorocystosine
  • 5-fluorocytosin
  • 5-fluoro-cytosin
  • fluocytosine
  • 4-Amino-5-Fluoro-2(1H)-pyrimidine, Flucytosine, 5-FC
  • 5-Fluorocytosine98%
  • 5-FLUOROCYTOSINE(FLUCYTOSINE)
  • FLUCYTOSINE (5-FLUOROCYTOSINE)
  • 5-Fluorocytosine,4-amino-5-fluoro-2(1H)-pyrimidinone, Flucytosine
  • Flucytosine (200 mg)G0E1511.000mg/mg(dr)
  • 5-FC,RO 2-9915
  • 4-Amino-5-fluoropyrimidin-2(1H)-one, 4-Amino-1,2-dihydro-5-fluoro-2-oxopyrimidine
  • 2(1H)-Pyrimidinone, 6-amino-5-fluoro-
  • 5-FLUOROCYTOSINE USP/BP
  • 6-Amino-5-fluoro-1H-pyrimidin-2-one
  • 5-FLUOROCYTOSINE extrapure
  • Flurocytosine
  • 4-amino-5-fluoro-2(1H)-pyrimidinone, Flucytosine
  • Emtricitabine Impurity Ⅰ：Flucytosine
  • Cytosine Impurity 3
  • 6-amino-5-fluoro-1,2-dihydropyrimidin-2-one
  • ro2-9915
  • TIMTEC-BB SBB000061
  • FLUCYSTINE
  • FLUCYTOSIN
  • FLUCYTOSINE
  • fluorocytosine
  • 5-FLUOROCYTOSINE
  • 5-FLUCYTOSINE
  • 5-FC
  • ancobon
  • ancotil
  • ALCOBON
  • 4-AMINO-5-FLUORO-2(1H)-PYRIMIDINE
  • 4-amino-5-fluoro-2(1h)-pyrimidinone
  • 4-AMINO-5-FLUORO-2-HYDROXYPYRIMIDINE
  • 4-AMINO-5-FLUORO-3H-PYRIMIDIN-2-ONE
  • 2-hydroxy-4-amino-5-fluoropyrimidine
  • 5-Flurocytosine
  • 4-amino-5-fluoropyrimidin-2(1H)-one
  • 5-FLUOR-CYTOSIN
  • 5-FLUROCYTOSINE/FLUCYTOSINE
  • FlucytosineTablets
  • 2(1H)-Pyrimidinone, 4-amino-5-fluoro- (9CI)
  • 4-Amino-5-fluoro-2[1H]-pyrimidone
  • 5-Fluorocytosine, 99+%
  • Flucytosine (200 mg)
  • NSC 103805 6-AMino-5-fluoro-
  • 4-Amino-5-fluoro-2-hydroxypyrimidine Flucytosine
  • 4-aMino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxyMethyl)oxolan-2-yl]-5-fluoro-1,2-dihydropyriMidin-2-one
  • 6-AMino-2-oxo-5-fluoropyriMidine
  • 5-Fluorocytosine USP/EP
  • 5 - fluorine cytosine
  • 6-amino-5-fluoro-2(1H)-pyrimidinone
  • Flucytosine for system suitability
  • 5-Fluorocytosine Vetec(TM) reagent grade, 99%